ReviewJournal of thoracic disease2026
2025 annual review of basic and translational research advances in pulmonary fibrosis: a narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Pulmonary fibrosis remains a major unresolved challenge in clinical practice. In 2025, pulmonary fibrosis research achieved a series of important advances. This article reviews the progress in basic and translational research of pulmonary fibrosis in 2025. Methods: To retrieve literature related to basic and translational research in pulmonary fibrosis, a keyword search was performed, which covered PubMed and Web of Science databases for publications from January 1, 2025 to December 31, 2025. Key Content and Findings: Advances in experimental models of pulmonary fibrosis-including animal models, lung-on-a-chip models, and biomaterial-based models-have enabled better recapitulation of pathological characteristics of the disease. At the mechanistic level, deeper insights regarding core pathological processes have been gained, including small-airway dysfunction, aberrant alveolar epithelial repair, profibrotic macrophage activation, adaptive immune niches, and pathological fibroblast transitions. At the translational level, approval of nerandomilast represented an important milestone, while artificial intelligence (AI)-derived compounds, niche-targeted intervention strategies, and combination therapies have broadened the landscape of anti-fibrotic drug development. Conclusions: In 2025, significant progress has been made in experimental models, mechanistic study, and drug development for pulmonary fibrosis. These advances are shifting the field from a focus on signaling pathways toward an integrative perspective, laying the foundation for in-depth understanding of complex pathological mechanisms of pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.